Streetbeat News

Analyst Ratings

AFG

Citigroup analyst Charlie Lederer has reaffirmed a Buy rating on American Financial Group (NYSE:AFG) and increased the price target from $125 to $131.

Portfolio Pulse from Benzinga Newsdesk

January 11, 2024 | 7:32 pm

LNT

Alliant Energy's stock (LNT) trades lower following a downgrade by BMO Capital from Outperform to Market Perform.

Portfolio Pulse from Benzinga Newsdesk

January 11, 2024 | 7:28 pm

ALB

Albemarle Corporation's stock (ALB) is trading lower after Deutsche Bank downgraded the stock from Buy to Hold.

Portfolio Pulse from Benzinga Newsdesk

January 11, 2024 | 7:27 pm

DCGO

DocGo Inc (NASDAQ:DCGO) responded to a short report by Fuzzy Panda, which accused the company of fraudulent billing and other illegal practices. DocGo refuted the claims, asserting its fiscal health and growth plans, with preliminary FY 2023 revenue of $615-$625 million and an expected increase in 2024 revenue to exceed $700 million. Needham maintained a Buy rating on DCGO with a $14 price target. DCGO shares rose 10.40% to $3.30 after the response.

Portfolio Pulse from Vandana Singh

January 11, 2024 | 7:15 pm

PEN

Penumbra (NYSE:PEN) received mixed analyst ratings over the last three months, with 6 analysts offering diverse perspectives. The average 12-month price target is $269.00, with a high of $295.00 and a low of $240.00. Recent actions include both raised and lowered price targets and ratings. Penumbra develops medical devices and has shown a revenue growth of 26.8% as of September 30, 2023. However, it has below-average net margin, ROE, and ROA, but a low debt-to-equity ratio of 0.21. The company's market capitalization is below industry averages.

Portfolio Pulse from Benzinga Insights

January 11, 2024 | 7:01 pm

ALB

Analysts have provided mixed reviews on Albemarle (NYSE:ALB) over the past three months, with recent sentiment shifting negatively. The average 12-month price target has been reduced by 19.97% to $171.67. Analysts from firms including UBS, Deutsche Bank, Keybanc, B of A Securities, Piper Sandler, BMO Capital, RBC Capital, and Oppenheimer have adjusted their ratings and price targets, mostly lowering them. Albemarle is a major lithium producer with strong market presence, revenue growth, net margin, ROE, and ROA, and a healthy debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

January 11, 2024 | 7:01 pm

STER

Sterling Check (NASDAQ:STER) has received mixed reviews from analysts over the past three months, with 3 bullish and 2 indifferent ratings. The average 12-month price target is $14.2, with a high of $16.00 and a low of $13.00, reflecting a 6.89% decrease in the average target. Analysts from Goldman Sachs and Morgan Stanley have adjusted their price targets and ratings, indicating a nuanced view of the company's prospects. Sterling Check's financial performance shows a decline in revenue growth, below-average net margin, ROE, and ROA, but a balanced debt approach. Benzinga's automated content engine generated the article, which was reviewed by an editor.

Portfolio Pulse from Benzinga Insights

January 11, 2024 | 7:00 pm

GLW

Seven analysts have recently provided their ratings on Corning (NYSE:GLW), with a mix of opinions. The average 12-month price target is $32.43, down 10.64% from the previous $36.29. Analysts from UBS, JP Morgan, Citigroup, Barclays, Oppenheimer, Morgan Stanley, and Deutsche Bank have adjusted their price targets and ratings, reflecting a cautious outlook. Corning's financial health shows a strong market position with a high market cap and net margin, but revenue decline and high debt-to-equity ratio present challenges.

Portfolio Pulse from Benzinga Insights

January 11, 2024 | 7:00 pm

SLG

SL Green Realty (NYSE:SLG) has been evaluated by 10 analysts over the last three months, with ratings ranging from bullish to bearish. The average 12-month price target is $42.7, up 5.96% from the previous $40.30. Analysts from firms like Goldman Sachs, Piper Sandler, Barclays, BMO Capital, and Truist Securities have updated their ratings and price targets, reflecting changes in market dynamics and company performance. SL Green Realty, a large Manhattan property owner, has seen a -18.47% decline in revenue growth and has a net margin of -13.84%, ROE of -0.62%, and ROA of -0.24%, with a debt-to-equity ratio of 1.14.

Portfolio Pulse from Benzinga Insights

January 11, 2024 | 7:00 pm

ACRS

Aclaris Therapeutics (NASDAQ:ACRS) has received mixed ratings from 4 analysts in the last three months, with 2 bullish and 2 indifferent ratings. The average 12-month price target is now $5.25, a significant drop from the previous $21.67. Analysts from HC Wainwright & Co. and Stifel have maintained and lowered their price targets, respectively, reflecting changes in market dynamics and company performance. Aclaris is a clinical-stage biopharmaceutical company with a focus on immuno-inflammatory diseases. Financially, the company has seen a -51.19% decline in revenue growth and has a net margin of -315.24%, with an ROE of -17.41% and an ROA of -12.89%. The company has no debt with a debt-to-equity ratio of 0.0.

Portfolio Pulse from Benzinga Insights

January 11, 2024 | 7:00 pm